CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD Funds and ETFs Chengdu Kanghong Pharmaceutical Group Co., Ltd
Equities
002773
CNE1000020C4
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.71 CNY | +0.66% |
|
-4.02% | +23.16% |
| 04-29 | Kanghong Pharmaceutical's Unit Gets US FDA's Green Light to Test Macular Degeneration Drug | MT |
| 04-29 | Kanghong Pharmaceutical's Unit Gets Nod to Trial Macular Degeneration Drug | MT |
ETFs positioned on Chengdu Kanghong Pharmaceutical Group Co., Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.87% | - |
Chengdu Kanghong Pharmaceutical Group Co., Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines, chemical drugs and biological products. The Companyâs main products include Conbercept Ophthalmic Injection, Songling capsules conducive to blood vessels, Keluoxin capsules, venlafaxine hydrochloride capsules and sustained release tablets, aripiprazole tablets and orally disintegrating tablets, mosapride citrate tablets and dispersible tablets, dexzopiclone tablets, Shuganjieyu capsules, Danshu capsules and Yiqing capsules, among others. The Company distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D-
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
22.71
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +23.16% | 2.89B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- 002773 Stock
- Funds and ETFs Chengdu Kanghong Pharmaceutical Group Co., Ltd
